Annual SG&A
$106.92 M
+$2.82 M+2.71%
31 December 2023
Summary:
Iovance Biotherapeutics annual selling, general & administrative expenses is currently $106.92 million, with the most recent change of +$2.82 million (+2.71%) on 31 December 2023. During the last 3 years, it has risen by +$46.71 million (+77.57%). IOVA annual SG&A is now at all-time high.IOVA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$39.55 M
-$15.00 K-0.04%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly selling, general & administrative expenses is currently $39.55 million, with the most recent change of -$15.00 thousand (-0.04%) on 30 September 2024. Over the past year, it has increased by +$12.59 million (+46.69%). IOVA quarterly SG&A is now -0.04% below its all-time high of $39.57 million, reached on 30 June 2024.IOVA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$8.67 B
-$410.00 M-4.97%
30 September 2024
Summary:
Iovance Biotherapeutics TTM selling, general & administrative expenses is currently -$8.67 billion, with the most recent change of -$410.00 million (-4.97%) on 30 September 2024. Over the past year, it has dropped by -$8.77 billion (-8475.05%). IOVA TTM SG&A is now -32216149.07% below its all-time high of $140.42 million, reached on 30 September 2024.IOVA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.7% | +46.7% | -8475.0% |
| 3 y3 years | +77.6% | +89.4% | -10000.0% |
| 5 y5 years | +276.1% | +294.4% | -10000.0% |
IOVA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +77.6% | -0.0% | +89.4% | -128.3% | at low |
| 5 y | 5 years | at high | +276.1% | -0.0% | +294.4% | -396.0% | at low |
| alltime | all time | at high | >+9999.0% | -0.0% | >+9999.0% | <-9999.0% | at low |
Iovance Biotherapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $39.55 M(-0.0%) | $140.42 M(+9.8%) |
| June 2024 | - | $39.57 M(+26.0%) | $127.83 M(+16.0%) |
| Mar 2024 | - | $31.39 M(+5.0%) | $110.19 M(+3.1%) |
| Dec 2023 | $106.92 M(+2.7%) | $29.90 M(+10.9%) | $106.92 M(+3.3%) |
| Sept 2023 | - | $26.96 M(+23.0%) | $103.48 M(-0.9%) |
| June 2023 | - | $21.93 M(-22.0%) | $104.41 M(-4.0%) |
| Mar 2023 | - | $28.12 M(+6.3%) | $108.81 M(+4.5%) |
| Dec 2022 | $104.10 M(+24.4%) | $26.46 M(-5.1%) | $104.10 M(+2.6%) |
| Sept 2022 | - | $27.89 M(+5.9%) | $101.48 M(+7.4%) |
| June 2022 | - | $26.33 M(+12.5%) | $94.48 M(+8.0%) |
| Mar 2022 | - | $23.41 M(-1.8%) | $87.46 M(+4.5%) |
| Dec 2021 | $83.66 M(+39.0%) | $23.85 M(+14.2%) | $83.66 M(+10.2%) |
| Sept 2021 | - | $20.89 M(+8.2%) | $75.90 M(+7.0%) |
| June 2021 | - | $19.31 M(-1.6%) | $70.93 M(+7.5%) |
| Mar 2021 | - | $19.62 M(+22.0%) | $65.97 M(+9.6%) |
| Dec 2020 | $60.21 M(+47.4%) | $16.08 M(+1.0%) | $60.21 M(+9.5%) |
| Sept 2020 | - | $15.92 M(+10.9%) | $55.00 M(+12.0%) |
| June 2020 | - | $14.35 M(+3.6%) | $49.11 M(+7.6%) |
| Mar 2020 | - | $13.86 M(+27.5%) | $45.63 M(+11.7%) |
| Dec 2019 | $40.85 M(+43.7%) | $10.87 M(+8.4%) | $40.85 M(+8.9%) |
| Sept 2019 | - | $10.03 M(-7.7%) | $37.50 M(+8.4%) |
| June 2019 | - | $10.87 M(+19.7%) | $34.59 M(+13.2%) |
| Mar 2019 | - | $9.08 M(+20.7%) | $30.55 M(+7.4%) |
| Dec 2018 | $28.43 M(+33.7%) | $7.53 M(+5.8%) | $28.43 M(+8.2%) |
| Sept 2018 | - | $7.11 M(+4.2%) | $26.28 M(+5.8%) |
| June 2018 | - | $6.83 M(-2.0%) | $24.83 M(+8.3%) |
| Mar 2018 | - | $6.96 M(+29.6%) | $22.94 M(+7.9%) |
| Dec 2017 | $21.26 M(-20.4%) | $5.38 M(-5.1%) | $21.26 M(-3.7%) |
| Sept 2017 | - | $5.66 M(+14.8%) | $22.07 M(-18.0%) |
| June 2017 | - | $4.93 M(-6.7%) | $26.90 M(-8.0%) |
| Mar 2017 | - | $5.29 M(-14.4%) | $29.23 M(+9.2%) |
| Dec 2016 | $26.70 M | $6.18 M(-41.1%) | $26.76 M(+7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | $10.50 M(+44.5%) | $25.00 M(+45.5%) |
| June 2016 | - | $7.26 M(+157.8%) | $17.19 M(+39.6%) |
| Mar 2016 | - | $2.82 M(-36.3%) | $12.31 M(-0.7%) |
| Dec 2015 | $12.39 M(+51.2%) | $4.42 M(+64.8%) | $12.39 M(+23.8%) |
| Sept 2015 | - | $2.68 M(+12.5%) | $10.01 M(+2.4%) |
| June 2015 | - | $2.38 M(-17.8%) | $9.77 M(+8.5%) |
| Mar 2015 | - | $2.90 M(+42.4%) | $9.00 M(+11.7%) |
| Dec 2014 | $8.19 M(+113.8%) | $2.04 M(-16.8%) | $8.06 M(+30.4%) |
| Sept 2014 | - | $2.45 M(+51.5%) | $6.18 M(-0.2%) |
| June 2014 | - | $1.62 M(-17.4%) | $6.19 M(+15.6%) |
| Mar 2014 | - | $1.96 M(+1140.1%) | $5.35 M(+39.7%) |
| Dec 2013 | $3.83 M(-40.8%) | $157.80 K(-93.6%) | $3.83 M(-25.6%) |
| Sept 2013 | - | $2.46 M(+215.6%) | $5.15 M(+26.6%) |
| June 2013 | - | $779.30 K(+79.2%) | $4.06 M(-12.8%) |
| Mar 2013 | - | $434.90 K(-70.5%) | $4.66 M(-28.0%) |
| Dec 2012 | $6.48 M(-66.4%) | $1.47 M(+6.9%) | $6.48 M(-10.9%) |
| Sept 2012 | - | $1.38 M(+0.1%) | $7.27 M(-37.9%) |
| June 2012 | - | $1.38 M(-38.8%) | $11.71 M(-44.0%) |
| Mar 2012 | - | $2.25 M(-0.8%) | $20.89 M(+8.2%) |
| Dec 2011 | $19.30 M(+2897.8%) | $2.27 M(-61.0%) | $19.30 M(+11.2%) |
| Sept 2011 | - | $5.81 M(-44.9%) | $17.36 M(+48.2%) |
| June 2011 | - | $10.56 M(+1504.3%) | $11.71 M(+918.4%) |
| Mar 2011 | - | $658.30 K(+102.8%) | $1.15 M(+133.9%) |
| Dec 2010 | $643.90 K(+2415.2%) | $324.60 K(+94.4%) | $491.60 K(+194.4%) |
| Sept 2010 | - | $167.00 K(+4671.4%) | $167.00 K(+963.7%) |
| Sept 2009 | - | $3500.00(+6.1%) | $15.70 K(+9.8%) |
| June 2009 | - | $3300.00(-50.0%) | $14.30 K(-2.7%) |
| Mar 2009 | - | $6600.00(+187.0%) | $14.70 K(-42.4%) |
| Dec 2008 | $25.60 K | $2300.00(+9.5%) | $25.50 K(+9.9%) |
| Sept 2008 | - | $2100.00(-43.2%) | $23.20 K(+10.0%) |
| June 2008 | - | $3700.00(-78.7%) | $21.10 K(+21.3%) |
| Mar 2008 | - | $17.40 K | $17.40 K |
FAQ
- What is Iovance Biotherapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual SG&A year-on-year change?
- What is Iovance Biotherapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly SG&A year-on-year change?
- What is Iovance Biotherapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM SG&A year-on-year change?
What is Iovance Biotherapeutics annual selling, general & administrative expenses?
The current annual SG&A of IOVA is $106.92 M
What is the all time high annual SG&A for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual selling, general & administrative expenses is $106.92 M
What is Iovance Biotherapeutics annual SG&A year-on-year change?
Over the past year, IOVA annual selling, general & administrative expenses has changed by +$2.82 M (+2.71%)
What is Iovance Biotherapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of IOVA is $39.55 M
What is the all time high quarterly SG&A for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly selling, general & administrative expenses is $39.57 M
What is Iovance Biotherapeutics quarterly SG&A year-on-year change?
Over the past year, IOVA quarterly selling, general & administrative expenses has changed by +$12.59 M (+46.69%)
What is Iovance Biotherapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of IOVA is -$8.67 B
What is the all time high TTM SG&A for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM selling, general & administrative expenses is $140.42 M
What is Iovance Biotherapeutics TTM SG&A year-on-year change?
Over the past year, IOVA TTM selling, general & administrative expenses has changed by -$8.77 B (-8475.05%)